AstraZeneca Pharmaceuticals, LP recalls BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceutical
Recalled July 19, 2017 · FDA recall D-0958-2017 · AstraZeneca Pharmaceuticals
Hazard
Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets. · FDA Class I
Units
40,368 bottles
Sold at
Nationwide in the USA and Puerto Rico to physician offices.
Description
Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.
Product
BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.
Manufacturer(s)
AstraZeneca Pharmaceuticals, LP
Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →